UNLABELLED: Although (123)I-MIBG has been in clinical use for the imaging of pheochromocytoma for many years, a large multicenter evaluation of this agent has never been performed. The present study was designed to provide a prospective confirmation of the performance of (123)I-MIBG scintigraphy for the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma. METHODS: A total of 81 patients with a prior history of primary or metastatic pheochromocytoma or paraganglioma and 69 with suspected pheochromocytoma or paraganglioma based on symptoms of catecholamine excess, CT or MRI findings, or elevated catecholamine or metanephrine levels underwent whole-body planar and selected SPECT 24 h after the administration of (123)I-MIBG. Images were independently interpreted by 3 masked readers, with consensus requiring agreement of at least 2 readers. Final diagnoses were based on histopathology, correlative imaging, catecholamine or metanephrine measurements, and clinical follow-up. RESULTS: Among 140 patients with definitive diagnoses (91, disease present; 49, disease absent), (123)I-MIBG planar scintigraphy had a sensitivity and specificity of 82%. For patients evaluated for suspected disease, sensitivity and specificity were 88% and 84%, respectively. For the subpopulations of adrenal (pheochromocytoma) and extraadrenal (paraganglioma) tumors, sensitivities were 88% and 67%, respectively. The addition of SPECT increased reader confidence but minimally affected sensitivity and specificity. CONCLUSION: This prospective study demonstrated a sensitivity of 82%-88% and specificity of 82%-84% for (123)I-MIBG imaging used in the diagnostic assessment of primary or metastatic pheochromocytoma or paraganglioma.
UNLABELLED: Although (123)I-MIBG has been in clinical use for the imaging of pheochromocytoma for many years, a large multicenter evaluation of this agent has never been performed. The present study was designed to provide a prospective confirmation of the performance of (123)I-MIBG scintigraphy for the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma. METHODS: A total of 81 patients with a prior history of primary or metastatic pheochromocytoma or paraganglioma and 69 with suspected pheochromocytoma or paraganglioma based on symptoms of catecholamine excess, CT or MRI findings, or elevated catecholamine or metanephrine levels underwent whole-body planar and selected SPECT 24 h after the administration of (123)I-MIBG. Images were independently interpreted by 3 masked readers, with consensus requiring agreement of at least 2 readers. Final diagnoses were based on histopathology, correlative imaging, catecholamine or metanephrine measurements, and clinical follow-up. RESULTS: Among 140 patients with definitive diagnoses (91, disease present; 49, disease absent), (123)I-MIBG planar scintigraphy had a sensitivity and specificity of 82%. For patients evaluated for suspected disease, sensitivity and specificity were 88% and 84%, respectively. For the subpopulations of adrenal (pheochromocytoma) and extraadrenal (paraganglioma) tumors, sensitivities were 88% and 67%, respectively. The addition of SPECT increased reader confidence but minimally affected sensitivity and specificity. CONCLUSION: This prospective study demonstrated a sensitivity of 82%-88% and specificity of 82%-84% for (123)I-MIBG imaging used in the diagnostic assessment of primary or metastatic pheochromocytoma or paraganglioma.
Authors: E van der Harst; W W de Herder ; H A Bruining; H J Bonjer; R R de Krijger ; S W Lamberts; A H van de Meiracker ; F Boomsma; T Stijnen; E P Krenning; F T Bosman; D J Kwekkeboom Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: Anouk N A Van Der Horst-Schrivers; Pieter L Jager; H Marike Boezen; Jan P Schouten; Ido P Kema; Thera P Links Journal: Anticancer Res Date: 2006 Mar-Apr Impact factor: 2.480
Authors: Judiann Miskulin; Barry L Shulkin; Gerard M Doherty; James C Sisson; Richard E Burney; Paul G Gauger Journal: Surgery Date: 2003-12 Impact factor: 3.982
Authors: M D Lynn; B Shapiro; J C Sisson; D P Swanson; T J Mangner; D M Wieland; L J Meyers; J V Glowniak; W H Beierwaltes Journal: J Nucl Med Date: 1984-04 Impact factor: 10.057
Authors: A H Elgazzar; M J Gelfand; L C Washburn; J Clark; N Nagaraj; D Cummings; J Hughes; H R Maxon Journal: Clin Nucl Med Date: 1995-02 Impact factor: 7.794
Authors: L Kölby; P Bernhardt; A-M Levin-Jakobsen; V Johanson; B Wängberg; H Ahlman; E Forssell-Aronsson; O Nilsson Journal: Br J Cancer Date: 2003-10-06 Impact factor: 7.640
Authors: Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak Journal: Endocr Relat Cancer Date: 2012-02-13 Impact factor: 5.678
Authors: Alexander Kroiss; Daniel Putzer; Christian Uprimny; Clemens Decristoforo; Michael Gabriel; Wolfram Santner; Christof Kranewitter; Boris Warwitz; Dietmar Waitz; Dorota Kendler; Irene Johanna Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2011-01-29 Impact factor: 9.236
Authors: Hiren V Patel; Arnav Srivastava; Murray D Becker; Toni Beninato; Amanda M Laird; Eric A Singer Journal: Curr Urol Rep Date: 2021-01-06 Impact factor: 3.092